Pyrazolopyrimidines as Cyclin Dependent Kinase Inhibitors

GUZI, Timothy, Kamil PARUCH, Michael DWYER, Ronald DOLL, Viyyoor GIRIJAVALLABHAN, Lawrence DILLARD, Vinh TRAN, Zhen HE, Ray JAMES and Haengsoon PARK. Pyrazolopyrimidines as Cyclin Dependent Kinase Inhibitors. 2004.

Basic information

Original name

Pyrazolopyrimidines as Cyclin Dependent Kinase Inhibitors

Name in Czech

Pyrazolopyrimidines as Cyclin Dependent Kinase Inhibitors

Authors

GUZI, Timothy (840 United States of America), Kamil PARUCH (203 Czech Republic, guarantor), Michael DWYER (840 United States of America), Ronald DOLL (840 United States of America), Viyyoor GIRIJAVALLABHAN (840 United States of America), Lawrence DILLARD (840 United States of America), Vinh TRAN (840 United States of America), Zhen HE (840 United States of America), Ray JAMES (840 United States of America) and Haengsoon PARK (840 United States of America)

Edition

Number: WO 2004/022559 A1, Publisher: World Intellectual Property Organization, Place of publication: USA, Owner's name: Schering Plough; Pharmacopeia, 2004

---

Other information

Language

English

Type of outcome

Patent

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

RIV identification code

RIV/00216224:14310/04:00035999

Organization unit

Faculty of Science

Keywords (in Czech)

cyclin dependent kinase; inhibitor; pyrazolopyrimidine

Keywords in English

cyclin dependent kinase; inhibitor; pyrazolopyrimidine

Tags

Cyclin dependent kinase, inhibitor, pyrazolopyrimidine

---

Abstract

V originále

The title pyrazolo[1,5-a]pyrimidines [I; R = (un)substituted heteroaryl; R2 = (un)substituted alkyl, alkynyl, aryl, heteroaryl, alkynylalkyl, CF3, heterocyclylalkyl, alkynylalkyl, cycloalkyl, CO2R4, etc., wherein aryl is optionally substituted; R3 = H, halogen, NR5R6, CO2R4, CONR5R6, each (un)substituted alkyl, alkynyl, cycloalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, or heteroaryl, etc.; R4 = H, halo, alkyl; R5 = H, alkyl; R6 = H, each (un)substituted alkyl, aryl, arylalkyl, cycloalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl; or R5 and R6 in the moiety -NR5R6, may be joined together to form an (un)substituted cycloalkyl or heterocyclyl] or pharmaceutically acceptable salts or solvates thereof are prepd. In its many embodiments, the present invention also provides methods of prepg. such compds., pharmaceutical compns. contg. one or more such compds. I, methods of prepg. pharmaceutical formulations comprising one or more such compds., and methods of treatment, prevention, inhibition, or amelioration of one or more diseases assocd. with cyclin dependent kinase using such compds. I or pharmaceutical compns. The disease assocd. with cyclin dependent kinase is selected from the group consisting of; (1) cancer of the bladder, breast, colon, kidney, liver, lung, small cell lung cancer, esophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; (2) leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkitt's lymphoma; (3) acute and chronic myelogenous leukemia, myelodysplastic syndrome and promyelocytic leukemia; (4) fibrosarcoma and rhabdomyosarcoma; (5) astrocytoma, neuroblastoma, glioma and schwannomas; and (6) melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoacanthoma, thyroid follicular cancer and Kaposi's sarcoma.

In Czech

viz Anotace